Recent Public Policy Activities

Buprenorphine 30 Patient Limit Letter (7.29.03)

Available in .pdf format (click here for help with .pdf files)

AAAP, ASAM, APA and AOAAM sent letters to Senators Hatch, Leahy, Gregg, and Kennedy and Representatives Tauzin and Dingell expressing their concern that a provision of the Drug Addiction Treatment Act of 2000 (DATA, Public Law 106-310) is having the unintended effect of limiting access of patients to treatment of their opiate dependence in office-based settings, and to ask for their assistance in remedying the problem.

Article about Dr. Richard N. Rosenthal's Testimony to the President's New Freedom Commission on Mental Health on January 8, 2003

New York State Psychiatric Association Bulletin Spring 2003 Pages 3-4

AAAP Addresses Health Resources and Services Administration on Strategic Plan for Interdisciplinary Faculty Development February 20, 2003 

Testimony of AAAP Secretary Dr. Joseph Liberto to the President's New Freedom Commission on Mental Health on February 5, 2003 

Testimony of AAAP Public Policy Section Head Dr. John T. Pichot at the Quality Treatment Policy Panel Hearing on February 3, 2003

AAAP Addresses CSAT on Strategic Plan for Interdisciplinary Faculty Development January 31, 2003

Testimony of AAAP President Dr. Richard N. Rosenthal to the President's New Freedom Commission on Mental Health on January 8, 2003

Links

Helpful Websites for Public Policy Advocacy at State and Federal Levels